New Preferred Products Categories for Dec. 9, 2024:
- VEGF: Bevacizumab preferred (Eylea, Eylea HD, Beovu, Byooviz, Cimerli, Lucentis, Susvimo, Vabysmo all step through bevacizumab).
- Hyaluronan: Gel-One, Synvisc, Synvisc-One preferred (Durolane, Euflexxa, Gelsyn-3, Genvisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz, Synojoynt, Triluron, TriVisc, Visco-3 all step through 1 preferred product).
- IV Iron: InFeD, Venofer, Feraheme, Ferrlecit preferred (Injectafer, Monoferric step through preferred iron product).
New Preferred Product Categories for Jan. 1, 2025:
- Prefer Tyenne (Actemra and Tofidence step through Tyenne).
- Rytelo non-preferred: Step through ESAs and Reblozyl in MDS RS+ patients.
- Piasky non-preferred: Step through 2 of Ultomiris, Empaveli, Fabhalta for PNH.
- Posfrea non-preferred: Step through generic J2469 Aloxi product.
- VEGF: Ahzantive, Enzeevu, Opuviz, Pavblu, Yesafil step through bevacizumab.
- Cinqair non-preferred: Step through self-administered product and provider administered preferred product (Nucala vial, Fasenra PFS).
Existing Preferred Product Categories - Continuing:
- Prefer Inflectra and Renflexis (Avsola, Infliximab unbranded, Remicade step through both Inflectra and Renflexis).
- LA CSFs: Fulphila, Neulasta preferred (Fylnetra, Nyvepria, Stimufend, Udenyca, Ziextenzo step thru Fulphila and Neulasta).
- Omvoh IV: Step through infliximab/infliximab biosimilar AND one additional preferred agent: Skyrizi, Entyvio, Stelara, or Tremfya.
- Orencia: Step thru preferred infliximab and Simponi Aria.
- Tysabri, Tyruko non-preferred. Step through *Preferred Crohn's Disease agents (adalimumab/adalimumab biosimilar, infliximab/infliximab biosimilar, Skyrizi (risankizumab-rzaa), Stelara (ustekinumab), Entyvio (Vedolizumab) - to be added for 1/1 policy as preferred option *Preferred generic Multiple Sclerosis agents dimethyl fumarate, fingolimod, glatiramer, Glatopa teriflunomide.
- Vyepti: Step thru 2 CGRPs or intolerance to all CGRPS.
Require a trial of the self-administered product before the healthcare administered product may be approved:
- Benlysta IV, Cosentyx IV, Fasenra, Nucala, Tezspire, Xolair.
Medical drugs that do not require precertification, but will have Post-Service Claim Edit (PSCE) policies:
- There will be medical drugs that will be reviewed using post-service claim edit (PSCE) policies. For a complete list of the PSCE policies, please visit www.gatewaypa.com/policydisplay/52.
- Starting Jan. 01, 2025 the following medical drugs will also have PSCE policies: Bortezomib, Nypozi, Pemetrexed.